image credit: Pexels

FDA expands probe into safety of AstraZeneca’s COVID-19 vaccine

October 1, 2020


The FDA has expanded its investigation into AstraZeneca’s COVID-19 vaccine to include data from clinical trials of prophylactics based on the same viral vector platform, Reuters reports.

AstraZeneca quickly gained regulatory clearance to resume dosing in the U.K. part of its development program after a case of transverse myelitis triggered a clinical hold. Regulators in Brazil, India and South Africa have also given AstraZeneca the green light to resume. However, the U.S. phase 3 is still on hold.

Read More on FierceBiotech